Nycomed US hasn't even been born yet, and it's already promising big growth.
Set to be spun off into an independent company once its Swiss parent Nycomed is bought out by Takeda Pharmaceutical, Nycomed US has tapped an executive team with ambitions for deals of their own. Brian Markison, who ran King Pharmaceutical until it was bought out by Pfizer, will take the helm at Nycomed US, backed up by several former King colleagues. As CEO, Markison plans an aggressive acquisition campaign to bulk up far beyond the unit's current $445 million in annual revenues. In fact, Markison told Dow Jones that he'd be surprised if Nycomed US isn't twice its current size within three years.
Mr. Markison said, "I am delighted, along with Jeff and John, to join the team at Nycomed US. This is an exciting time for the company because we have the opportunity to grow aggressively and forge our future as an independent entity. Jeff and John are great additions to an already strong and focused management team and I am confident we can leverage the Company's financial strength and unique platform within the dermatology market to drive further growth in our business."